Prospective Grant of Start-up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers, 15226-15227 [2015-06486]

Download as PDF 15226 Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings mstockstill on DSK4VPTVN1PROD with NOTICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; New Approaches to Synthetic Lethality for Mutant KRas-Dependent Cancers (U01). Date: April 13, 2015. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove; 9609 Medical Center Drive; Room 7W032; Rockville, MD 20850; (Telephone Conference Call). Contact Person: Clifford W. Schweinfest, Ph.D.; Scientific Review Officer; Special Review Branch; Division of Extramural Activities; National Cancer Institute, NIH; 9609 Medical Center Drive, Room 7W108; Bethesda, MD 20892–9750; 240–276–6343; schweinfestcw@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Subcommittee A—Cancer Centers. Date: May 7, 2015. Time: 8:00 a.m. to 4:45 p.m. Agenda: To review and evaluate grant applications. Place: Doubletree Hotel Bethesda; (Formerly Holiday Inn Select); 8120 Wisconsin Avenue; Bethesda, MD 20814. Contact Person: Shamala K. Srinivas, Ph.D.; Associate Director; Office of Referral, Review, and Program Coordination; Division of Extramural Activities; National Cancer Institute, NIH; 9609 Medical Center Drive, 7W530; Bethesda, MD 20892–9750; 240–276– 6442; ss537t@nih.gov. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/sep/sep.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology VerDate Sep<11>2014 16:51 Mar 20, 2015 Jkt 235001 Dated: March 17, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–06477 Filed 3–20–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Start-up Exclusive Evaluation Option License Agreement: Pre-Clinical Evaluation and Commercial Development of AntiTyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the Treatment of Human Cancers AGENCY: National Institutes of Health, HHS. ACTION: Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive evaluation option license agreement to practice the inventions embodied in U.S. Patent Application No. 61/172,099 entitled ‘‘Anti-human ROR1 Antibodies’’ filed April 23, 2009 [HHS Ref. E–097–2009/ 0–US–01], PCT Application No. PCT/ US2010/032208 entitled ‘‘Anti-human ROR1 Antibodies’’ filed April 23, 2010 [HHS Ref. E–097–2009/0–PCT–02], European Patent Application No. 10715077.3 entitled, ‘‘Anti-human ROR1 Antibodies’’ filed October 24, 2011 [HHS Ref. No. E–097–2009/0–EP– 03], U.S. Patent Application No. 13/ 265,582 entitled, ‘‘Anti-human ROR1 Antibodies’’ filed October 21, 2011 [HHS Ref. No. E–097–2009/0–US–04], Australian Patent Application No. 2010238723 entitled, ‘‘Anti-human ROR1 Antibodies’’ filed October 21, 2011 [HHS Ref. No. E–097–2009/0–AU– 04], Canadian Patent Application No. 2,759,733 entitled, ‘‘Anti-human ROR1 Antibodies’’ filed October 21, 2011 [HHS Ref. No. E–097–2009/0–CA–05], US Provisional Application No. 61/ 418,550 entitled, ‘‘Chimeric rabbit/ human ROR1 antibodies’’ filed December 1, 2010 [HHS Ref. E–039– 2011/0–US–01], PCT Application No. PCT/US2011/062670 entitled, ‘‘Chimeric rabbit/human ROR1 antibodies’’ filed November 30, 2011 [HHS Ref. E–039–2011/0–PCT–02]; SUMMARY: PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 Australian Patent Application No. 2011336650 entitled, ‘‘Chimeric rabbit/ human ROR1 antibodies’’ filed November 30, 2011 [HHS Ref. E–039– 2011/0–AU–03], Canadian Patent Application No. 2818992 entitled, ‘‘Chimeric rabbit/human ROR1 antibodies’’ filed November 30, 2011 [HHS Ref. E–039–2011/0–CA–04], European Patent Application No. 11791733.6 entitled, ‘‘Chimeric rabbit/ human ROR1 antibodies’’ filed November 30, 2011 [HHS Ref. E–039– 2011/0–EP–05] and U.S. Patent Application No. 13/990,977 entitled, ‘‘Chimeric rabbit/human ROR1 antibodies’’ filed May 31, 2013 [HHS Ref. E–039–2011/0–US–06] and all related continuing and foreign patents/ patent applications for the technology family to NBE Therapeutics, Ltd. The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective start-up exclusive evaluation option license territory may be worldwide and the field of use may be limited to pre-clinical evaluation and commercial development of an antibody-drug conjugate comprising an anti-tyrosine protein kinase transmembrane receptor (ROR1) antibody for the treatment of human ROR1 expressing cancers utilizing enzymatic conjugation methods linking a small molecule to a full-length antibody, wherein the full-length antibody moiety comprises the antiROR1 antibodies or CDR3s within the scope of the Licensed Patent Rights. For avoidance of doubt, this Agreement explicitly excludes the following: (a) Antibody-drug conjugates utilizing nonenzymatic conjugation linking small molecules to said antibodies, (b) immunotoxins comprising anti-ROR1 antibodies and Pseudomonas exotoxins, and (c) non-full-length bispecific antibodies. Upon expiration or termination of the start-up exclusive evaluation option license, NBE Therapeutics, Ltd. will have the right to execute a start-up exclusive patent commercialization license which will supersede and replace the start-up exclusive evaluation option license with no broader territory than granted in the start-up exclusive evaluation option license and the field of use will be commensurate with the commercial development plan at the time of conversion. Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 6, 2015 will be considered. DATED: E:\FR\FM\23MRN1.SGM 23MRN1 Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices Requests for copies of the patent applications, inquiries, comments, and other materials relating to the contemplated exclusive evaluation option license should be directed to: Jennifer Wong, M.S., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435– 4633; Facsimile: (301) 402–0220; Email: wongje@od.nih.gov. ADDRESSES: Tyrosine kinase-like orphan receptor 1 (ROR1) is a signature cell surface antigen for B-cell malignancies, most notably, B-cell chronic lymphocytic leukemia (B–CLL) and mantle cell lymphoma (MCL) cells, two incurable diseases. The investigators have developed a portfolio of chimeric anti-ROR1 monoclonal antibodies that selectively target ROR1 malignant B-cells but not normal Bcells. These antibodies may be linked to chemical drugs or biological toxins thus providing targeted cytotoxic delivery to malignant B-cells while sparing normal cells. Moreover, as these antibodies selectively target ROR1, they can also be used to diagnose B-cell malignancies. The prospective start-up exclusive evaluation option license is being considered under the small business initiative launched on October 1, 2011 and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective start-up exclusive evaluation option license, and a subsequent start-up exclusive patent commercialization license, may be granted unless within fifteen (15) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Any additional, properly filed, and complete applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated start-up exclusive evaluation option license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. mstockstill on DSK4VPTVN1PROD with NOTICES SUPPLEMENTARY INFORMATION: Dated: March 16, 2015. Richard U. Rodriguez, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2015–06486 Filed 3–20–15; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 16:51 Mar 20, 2015 Jkt 235001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2); notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Feb2015 Cycle 19 NExT SEP Committee Meeting. Date: April 29, 2015. Time: 8:30 a.m. to 4:30 p.m. Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio. Place: National Institutes of Health, 9000 Rockville Pike, Campus Building 31, Conference Room 6C10, Bethesda, MD 20892. Contact Persons: Barbara Mroczkowski, Ph.D., Executive Secretary, Discovery Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496–4291, mroczkoskib@mail.nih.gov; Joseph Tomaszewski, Ph.D., Executive Secretary, Development Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20817, (301) 496–6711, tomaszej@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 15227 Dated: March 17, 2015. Melanie J. Gray, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–06476 Filed 3–20–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Drug Discovery. Date: April 2, 2015. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Peter B. Guthrie, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4142, MSC 7850, Bethesda, MD 20892, (301) 435– 1239, guthriep@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Exercise in aging, ischemia imaging. Date: April 2, 2015. Time: 12:01 p.m. to 1:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Samuel C. Edwards, Ph.D., IRG CHIEF, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5210, MSC 7846, Bethesda, MD 20892, (301) 435–1246, edwardss@csr.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. E:\FR\FM\23MRN1.SGM 23MRN1

Agencies

[Federal Register Volume 80, Number 55 (Monday, March 23, 2015)]
[Notices]
[Pages 15226-15227]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-06486]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-up Exclusive Evaluation Option License 
Agreement: Pre-Clinical Evaluation and Commercial Development of Anti-
Tyrosine Kinase-Like Orphan Receptor 1 Antibody-Drug Conjugates for the 
Treatment of Human Cancers

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of a start-up exclusive 
evaluation option license agreement to practice the inventions embodied 
in U.S. Patent Application No. 61/172,099 entitled ``Anti-human ROR1 
Antibodies'' filed April 23, 2009 [HHS Ref. E-097-2009/0-US-01], PCT 
Application No. PCT/US2010/032208 entitled ``Anti-human ROR1 
Antibodies'' filed April 23, 2010 [HHS Ref. E-097-2009/0-PCT-02], 
European Patent Application No. 10715077.3 entitled, ``Anti-human ROR1 
Antibodies'' filed October 24, 2011 [HHS Ref. No. E-097-2009/0-EP-03], 
U.S. Patent Application No. 13/265,582 entitled, ``Anti-human ROR1 
Antibodies'' filed October 21, 2011 [HHS Ref. No. E-097-2009/0-US-04], 
Australian Patent Application No. 2010238723 entitled, ``Anti-human 
ROR1 Antibodies'' filed October 21, 2011 [HHS Ref. No. E-097-2009/0-AU-
04], Canadian Patent Application No. 2,759,733 entitled, ``Anti-human 
ROR1 Antibodies'' filed October 21, 2011 [HHS Ref. No. E-097-2009/0-CA-
05], US Provisional Application No. 61/418,550 entitled, ``Chimeric 
rabbit/human ROR1 antibodies'' filed December 1, 2010 [HHS Ref. E-039-
2011/0-US-01], PCT Application No. PCT/US2011/062670 entitled, 
``Chimeric rabbit/human ROR1 antibodies'' filed November 30, 2011 [HHS 
Ref. E-039-2011/0-PCT-02]; Australian Patent Application No. 2011336650 
entitled, ``Chimeric rabbit/human ROR1 antibodies'' filed November 30, 
2011 [HHS Ref. E-039-2011/0-AU-03], Canadian Patent Application No. 
2818992 entitled, ``Chimeric rabbit/human ROR1 antibodies'' filed 
November 30, 2011 [HHS Ref. E-039-2011/0-CA-04], European Patent 
Application No. 11791733.6 entitled, ``Chimeric rabbit/human ROR1 
antibodies'' filed November 30, 2011 [HHS Ref. E-039-2011/0-EP-05] and 
U.S. Patent Application No. 13/990,977 entitled, ``Chimeric rabbit/
human ROR1 antibodies'' filed May 31, 2013 [HHS Ref. E-039-2011/0-US-
06] and all related continuing and foreign patents/patent applications 
for the technology family to NBE Therapeutics, Ltd. The patent rights 
in these inventions have been assigned to the Government of the United 
States of America.
    The prospective start-up exclusive evaluation option license 
territory may be worldwide and the field of use may be limited to pre-
clinical evaluation and commercial development of an antibody-drug 
conjugate comprising an anti-tyrosine protein kinase transmembrane 
receptor (ROR1) antibody for the treatment of human ROR1 expressing 
cancers utilizing enzymatic conjugation methods linking a small 
molecule to a full-length antibody, wherein the full-length antibody 
moiety comprises the anti-ROR1 antibodies or CDR3s within the scope of 
the Licensed Patent Rights. For avoidance of doubt, this Agreement 
explicitly excludes the following: (a) Antibody-drug conjugates 
utilizing non-enzymatic conjugation linking small molecules to said 
antibodies, (b) immunotoxins comprising anti-ROR1 antibodies and 
Pseudomonas exotoxins, and (c) non-full-length bispecific antibodies. 
Upon expiration or termination of the start-up exclusive evaluation 
option license, NBE Therapeutics, Ltd. will have the right to execute a 
start-up exclusive patent commercialization license which will 
supersede and replace the start-up exclusive evaluation option license 
with no broader territory than granted in the start-up exclusive 
evaluation option license and the field of use will be commensurate 
with the commercial development plan at the time of conversion.

DATED: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
April 6, 2015 will be considered.

[[Page 15227]]


ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments, and other materials relating to the contemplated exclusive 
evaluation option license should be directed to: Jennifer Wong, M.S., 
Senior Licensing and Patenting Manager, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Telephone: (301) 435-4633; Facsimile: (301) 
402-0220; Email: wongje@od.nih.gov.

SUPPLEMENTARY INFORMATION: Tyrosine kinase-like orphan receptor 1 
(ROR1) is a signature cell surface antigen for B-cell malignancies, 
most notably, B-cell chronic lymphocytic leukemia (B-CLL) and mantle 
cell lymphoma (MCL) cells, two incurable diseases. The investigators 
have developed a portfolio of chimeric anti-ROR1 monoclonal antibodies 
that selectively target ROR1 malignant B-cells but not normal B-cells. 
These antibodies may be linked to chemical drugs or biological toxins 
thus providing targeted cytotoxic delivery to malignant B-cells while 
sparing normal cells. Moreover, as these antibodies selectively target 
ROR1, they can also be used to diagnose B-cell malignancies.
    The prospective start-up exclusive evaluation option license is 
being considered under the small business initiative launched on 
October 1, 2011 and will comply with the terms and conditions of 35 
U.S.C. 209 and 37 CFR part 404. The prospective start-up exclusive 
evaluation option license, and a subsequent start-up exclusive patent 
commercialization license, may be granted unless within fifteen (15) 
days from the date of this published notice, the NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR part 404.
    Any additional, properly filed, and complete applications for a 
license in the field of use filed in response to this notice will be 
treated as objections to the grant of the contemplated start-up 
exclusive evaluation option license. Comments and objections submitted 
to this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: March 16, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-06486 Filed 3-20-15; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.